Fovea Pharmaceuticals
Paris
About Fovea Pharmaceuticals
Fovea Pharmaceuticals is a French biopharmaceutical company. It discovers and develops drugs for the treatment of ocular diseases. The company offers FOV1101 Prednisporin for the treatment of allergic conjunctivitis; FOV2302, a proprietary plasma kallikrein-kinin inhibitor for the systemic treatment of hereditary angioedema; FOV2304 for the treatment of diabetic macular edema; and FOV2501, an intravitreal formulation of RdCVF designed to treat retinitis pigmentosa with extension to dry age-related macular degeneration. Fovea Pharmaceuticals was founded in 2005 and is based in Paris, France. As of October 30, 2009, it operates as a subsidiary of Sanofi.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Total funding: $107.0M
- Funding stage: M&A
- Last round: Series B (Dec 2007)
- Website: fovea-pharma.com
Industries & Categories
Biotechnology, Health Care, Medical, Pharmaceutical
Canonical: https://fsome.com/organization/fovea-pharmaceuticals-3148874 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.